Blueprint Medicines Corporation

Thomas A Dineen

Timothy J Guzi

Jason D Brubaker

Emanuele Perola

Joseph L Kim

Douglas Wilson

Chandrasekhar V Miduturu

Joshua T Close

Kevin J Wilson

John Emmerson Campbell

Natasja Brooijmans

Brett D Williams

Michael J Burke

Christopher De Savi

Meredith Suzanne Eno

Aysegül Özen

Yinghui Dai

Guangyan Du

Thiwanka Samarakoon

Cheng Fang

Andrew Marc Haidle

Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.

Wild type kit inhibitors

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

MAP4K1 inhibitors

The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

EGFR inhibitors

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFR&#x3b1; and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFR&#x3b1;. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

Compositions and methods for treating KIT- and PDGFRA-mediated diseases

Growing community of inventors

Cambridge, MA, United States of America

Thomas A Dineen